Video Insights
Advertisement
Advertisement
The panel discussed novel targeted combinations in CNS lymphoma, such as BTK inhibitors in combination with IRAK inhibitors.
The panel, moderated by Grzegorz Nowakowski, MD, discussed how to manage methotrexate toxicity in CNS lymphoma.
The COMMANDS trial evaluated frontline luspatercept in transfusion-dependent patients with lower-risk MDS and anemia.
A database study has identified an association between disease stage at lymphoma diagnosis and time of Medicaid enrollment.
Moderated by Amer M. Zeidan, MBBS, a panel discusses the critical roles of patient fitness, genetics in AML treatment.
This expert panel shares insights into the latest advancements, clinical challenges in AML and more.
Gain valuable insights from leading experts as they explore how targeted therapies are shaping the future of AML management.
The panel moderated by Prithviraj Bose, MD, goes into detail on practical aspects of this agent's use in the clinic.
The expert panel moderated by Dr. Bose looks at noteworthy study work on use of this agent for anemia in myelofibrosis.
Empaneled experts describe their investigations of momelotinib in a continued discussion moderated by Prithviraj Bose, MD.
The expert panel moderated by Prithviraj Bose, MD, tells which research presented at the Meeting they found most exciting.
Esteemed experts provide valuable insights into the evolving myelofibrosis landscape and its implications for patient care.
Key takeaways from the top ASH abstracts in the myelofbrosis space.
A roundtale discussion starts with a conversation about the myelofibrosis treatment landscape.
An expert speaks on site at ASH 2024 about the health-related quality of life data from the phase 3 COMMANDS trial.
An expert's insights on the latest advancements in MF treatment presented at the ASH 2024 meeting.
There may be a link between obesity and how myeloproliferative neoplasms develop, research shows.
A discussion on the post hoc analysis on quality of life from the COMMANDS trial.
Discussing the COMMANDS trial and sequencing luspatercept in patients with myelodysplastic syndromes.
How to address ESA failure or ineligibility in patients with MDS...
Results from a real-world analysis of post-ESA treatment outcomes in patients with lower-risk myelodysplastic syndrome.
Noa Biran, MD reviews a clinical trial of SPd for relapsed or refractory multiple myeloma.
Discussing current clinical trials iand unmet needs in myelofibrosis.
Rahul Banerjee, MD, of the Fred Hutchinson Cancer Center, discusses notable studies in myeloma presented at ASH 2024.
The panel, moderated by Grzegorz Nowakowski, MD, also assessed the feasibility of a CSF biomarker for this disease.
Transplantation and radiation are prominent topics in this expert panel segment, moderated by Grzegorz Nowakowski, MD.
The panel, moderated by Grzegorz Nowakowski, MD, discussed options like lenalidomide, BTK inhibitors, and clinical trials.
Grzegorz Nowakowski, MD, asks an expert panel about their approaches and special issues they encounter in first-line care.
In this roundtable segment, the panel discussed imetelstat for the treatment of lower-risk MDS.
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss which patients with MDS should be treated with luspatercept.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.